A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

To join this study, you must have a confirmed diagnosis of advanced liver cancer (hepatocellular carcinoma) and your doctors must be able to measure your cancer to track how it responds to treatment. You also can't have received any previous medication for your advanced liver cancer.

Your liver health must be generally good, as measured by a score called Child-Pugh 5 or 6, and your general health and how well you can go about your daily activities should be quite good (known as an ECOG performance status of 0 or 1).

However, there are certain reasons why you might not be able to join. For example, if you have a specific rare type of liver cancer (like fibrolamellar HCC), have had a liver transplant, or have experienced severe confusion due to liver problems in the last year. Also, if your cancer has spread to your brain or the lining around it, you wouldn't be able to participate.

If you decide to join this study, you'll be assigned to receive either the combination of nivolumab and ipilimumab or one of the standard treatments (sorafenib or lenvatinib). You won't get to choose which treatment you receive. You'll have regular visits to the hospital or clinic for blood tests, physical exams, and scans to check on your health and how the treatment is working. Doctors and nurses will explain when and how often you'll need to take the medication, which could be in the form of injections or pills.

Throughout the study, your health will be carefully monitored, and any side effects you experience will be recorded. The exact number of visits, tests, and the total length of time you'll be in the study will be explained in detail by the study team. This generally involves a period of active treatment followed by follow-up appointments.